249 related articles for article (PubMed ID: 34916609)
1. Lupeol protects against cardiac hypertrophy via TLR4-PI3K-Akt-NF-κB pathways.
Li D; Guo YY; Cen XF; Qiu HL; Chen S; Zeng XF; Zeng Q; Xu M; Tang QZ
Acta Pharmacol Sin; 2022 Aug; 43(8):1989-2002. PubMed ID: 34916609
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-(3-7) alleviates isoprenaline-induced cardiac remodeling via attenuating cAMP-PKA and PI3K/Akt signaling pathways.
Zhang Y; Shang Z; Liu A
Amino Acids; 2021 Oct; 53(10):1533-1543. PubMed ID: 34494132
[TBL] [Abstract][Full Text] [Related]
3. Pinoresinol diglucoside (PDG) attenuates cardiac hypertrophy via AKT/mTOR/NF-κB signaling in pressure overload-induced rats.
Chen Y; Pan R; Zhang J; Liang T; Guo J; Sun T; Fu X; Wang L; Zhang L
J Ethnopharmacol; 2021 May; 272():113920. PubMed ID: 33607200
[TBL] [Abstract][Full Text] [Related]
4. Triad3A attenuates pathological cardiac hypertrophy involving the augmentation of ubiquitination-mediated degradation of TLR4 and TLR9.
Lu X; He Y; Tang C; Wang X; Que L; Zhu G; Liu L; Ha T; Chen Q; Li C; Xu Y; Li J; Li Y
Basic Res Cardiol; 2020 Feb; 115(2):19. PubMed ID: 32008145
[TBL] [Abstract][Full Text] [Related]
5. Phillyrin attenuates norepinephrine-induced cardiac hypertrophy and inflammatory response by suppressing p38/ERK1/2 MAPK and AKT/NF-kappaB pathways.
Tang K; Zhong B; Luo Q; Liu Q; Chen X; Cao D; Li X; Yang S
Eur J Pharmacol; 2022 Jul; 927():175022. PubMed ID: 35569549
[TBL] [Abstract][Full Text] [Related]
6. Didymin ameliorates dexamethasone-induced non-alcoholic fatty liver disease by inhibiting TLR4/NF-κB and PI3K/Akt pathways in C57BL/6J mice.
Feng Z; Pang L; Chen S; Pang X; Huang Y; Qiao Q; Wang Y; Vonglorkham S; Huang Q; Lin X; Wei J
Int Immunopharmacol; 2020 Nov; 88():107003. PubMed ID: 33182043
[TBL] [Abstract][Full Text] [Related]
7. Curcumol alleviates cardiac remodeling via the AKT/NF-κB pathway.
Fang Z; Li S; Yushanjiang F; Feng G; Cui S; Hu S; Jiang X; Liu C
Int Immunopharmacol; 2023 Sep; 122():110527. PubMed ID: 37392572
[TBL] [Abstract][Full Text] [Related]
8. Bacillus Calmette-Guérin and TLR4 agonist prevent cardiovascular hypertrophy and fibrosis by regulating immune microenvironment.
Liu YY; Cai WF; Yang HZ; Cui B; Chen ZR; Liu HZ; Yan J; Jin W; Yan HM; Xin BM; Yuan B; Hua F; Hu ZW
J Immunol; 2008 Jun; 180(11):7349-57. PubMed ID: 18490734
[TBL] [Abstract][Full Text] [Related]
9. Tripartite motif 27 promotes cardiac hypertrophy via PTEN/Akt/mTOR signal pathways.
Chen Y; Liu Z; Hu Z; Feng X; Zuo L
Bioengineered; 2022 Apr; 13(4):8323-8333. PubMed ID: 35311628
[TBL] [Abstract][Full Text] [Related]
10. Lupeol modulates NF-kappaB and PI3K/Akt pathways and inhibits skin cancer in CD-1 mice.
Saleem M; Afaq F; Adhami VM; Mukhtar H
Oncogene; 2004 Jul; 23(30):5203-14. PubMed ID: 15122342
[TBL] [Abstract][Full Text] [Related]
11. Melatonin ameliorates pressure overload-induced cardiac hypertrophy by attenuating Atg5-dependent autophagy and activating the Akt/mTOR pathway.
Xu CN; Kong LH; Ding P; Liu Y; Fan ZG; Gao EH; Yang J; Yang LF
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165848. PubMed ID: 32473999
[TBL] [Abstract][Full Text] [Related]
12. Isorhamnetin protects against cardiac hypertrophy through blocking PI3K-AKT pathway.
Gao L; Yao R; Liu Y; Wang Z; Huang Z; Du B; Zhang D; Wu L; Xiao L; Zhang Y
Mol Cell Biochem; 2017 May; 429(1-2):167-177. PubMed ID: 28176246
[TBL] [Abstract][Full Text] [Related]
13. Protective Roles of Interferon-γ in Cardiac Hypertrophy Induced by Sustained Pressure Overload.
Kimura A; Ishida Y; Furuta M; Nosaka M; Kuninaka Y; Taruya A; Mukaida N; Kondo T
J Am Heart Assoc; 2018 Mar; 7(6):. PubMed ID: 29555642
[TBL] [Abstract][Full Text] [Related]
14. The TIR/BB-loop mimetic AS-1 prevents cardiac hypertrophy by inhibiting IL-1R-mediated MyD88-dependent signaling.
Zhu Y; Li T; Song J; Liu C; Hu Y; Que L; Ha T; Kelley J; Chen Q; Li C; Li Y
Basic Res Cardiol; 2011 Sep; 106(5):787-99. PubMed ID: 21533832
[TBL] [Abstract][Full Text] [Related]
15. Oleanonic acid ameliorates pressure overload-induced cardiac hypertrophy in rats: The role of PKCζ-NF-κB pathway.
Gao H; Liu H; Tang T; Huang X; Wang D; Li Y; Huang P; Peng Y
Mol Cell Endocrinol; 2018 Jul; 470():259-268. PubMed ID: 29138023
[TBL] [Abstract][Full Text] [Related]
16. Tamarixetin protects against cardiac hypertrophy via inhibiting NFAT and AKT pathway.
Fan C; Li Y; Yang H; Cui Y; Wang H; Zhou H; Zhang J; Du B; Zhai Q; Wu D; Chen X; Guo H
J Mol Histol; 2019 Aug; 50(4):343-354. PubMed ID: 31111288
[TBL] [Abstract][Full Text] [Related]
17. MiR-217 inhibits apoptosis of atherosclerotic endothelial cells via the TLR4/PI3K/Akt/NF-κB pathway.
Zhang B; Zhang YF; Li R; Zhao L; Qin SG; Pan LF; Gao YX
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12867-12877. PubMed ID: 33378037
[TBL] [Abstract][Full Text] [Related]
18. Hyperoside Protects Against Pressure Overload-Induced Cardiac Remodeling via the AKT Signaling Pathway.
Wang X; Liu Y; Xiao L; Li L; Zhao X; Yang L; Chen N; Gao L; Zhang J
Cell Physiol Biochem; 2018; 51(2):827-841. PubMed ID: 30466089
[TBL] [Abstract][Full Text] [Related]
19. JMJD6 protects against isoproterenol-induced cardiac hypertrophy via inhibition of NF-κB activation by demethylating R149 of the p65 subunit.
Guo Z; Hu YH; Feng GS; Valenzuela Ripoll C; Li ZZ; Cai SD; Wang QQ; Luo WW; Li Q; Liang LY; Wu ZK; Zhang JG; Javaheri A; Wang L; Lu J; Liu PQ
Acta Pharmacol Sin; 2023 Sep; 44(9):1777-1789. PubMed ID: 37186122
[TBL] [Abstract][Full Text] [Related]
20. Pristimerin protects against pathological cardiac hypertrophy through improvement of PPARα pathway.
Lu Y; Zeng Z; Bao X; Wu M; Jing Z; Feng J
Toxicol Appl Pharmacol; 2023 Aug; 473():116572. PubMed ID: 37269933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
